Asset profile
Bortezomib
Small molecule
Approvedregulatory verdict
Evidence outlook
Approved: Multiple Myeloma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Weak signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
63 competitors in this universe: 3 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Bortezomib: this drug | Approved | Small molecule | Proteasome | ||
| Carfilzomib | Approved | Small molecule | Proteasome | ||
| Ixazomib | Approved | Small molecule | Proteasome | ||
| TQB3602 | Phase 1 | Small molecule | Proteasome | ||
| Belantamab Mafodotin | Approved | Antibody–drug conjugate | BCMA | ||
| Ciltacabtagene Autoleucel | Approved | Cell therapy | BCMA | ||
| Daratumumab | Approved | Monoclonal antibody | CD38 | ||
| Denosumab | Approved | Monoclonal antibody | RANKL | ||
| Elotuzumab | Approved | Monoclonal antibody | SLAMF7 (CS1/CD319) | ||
| Elranatamab | Approved | Multispecific antibody | BCMA x CD3 | ||
| Idecabtagene Vicleucel | Approved | Cell therapy | BCMA | ||
| Isatuximab | Approved | Monoclonal antibody | CD38 | ||
| Lenalidomide | Approved | Small molecule | Cereblon E3 ubiquitin-ligase, Thalidomide Analog | ||
| Linvoseltamab | Approved | Multispecific antibody | BCMA x CD3 | ||
| Melphalan Flufenamide | Approved | Small molecule | DNA (alkylation), delivered via aminopeptidase-mediated intracellular activation | ||
| Melphalan Hydrochloride (Evomela) | Approved | Small molecule | DNA (guanine N7 position) |
…and 48 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(85 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (14)
October 2026 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2026-10-20 · NCT06140966 · CT.gov ↗
What to watch
November 2026 (2)
December 2026 (11)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2026-12 · NCT02718833 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2026-12 · NCT04268199 · CT.gov ↗
What to watch
Phase 2Metastatic Castration-resistant Prostate CancerActive not recruiting
Est. primary completion 2026-12 · NCT06029998 · CT.gov ↗
What to watch
Phase 2Systemic AmyloidosisRecruiting
Est. primary completion 2026-12 · NCT06342466 · CT.gov ↗
What to watch
Phase 2Mantle Cell LymphomaNot yet recruiting
Est. primary completion 2026-12-01 · NCT06656221 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2026-12-28 · NCT03729804 · CT.gov ↗
What to watch
Phase 1/2GlioblastomaRecruiting
Est. primary completion 2026-12-30 · NCT03643549 · CT.gov ↗
What to watch
Phase 3Plasma Cell MyelomaActive not recruiting
Est. primary completion 2026-12-31 · NCT01863550 · CT.gov ↗
What to watch
Phase 1Breast CancerRecruiting
Est. primary completion 2026-12-31 · NCT04265872 · CT.gov ↗
What to watch
Phase 1/2Recurrent Plasma Cell Myeloma, Refractory Plasma Cell MyelomaActive not recruiting
Est. primary completion 2026-12-31 · NCT05514990 · CT.gov ↗
What to watch
Phase 3T-cell Lymphoblastic LymphomaRecruiting
Est. primary completion 2026-12-31 · NCT05681260 · CT.gov ↗
What to watch
2027 (33)
January 2027 (2)
February 2027 (3)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-02-01 · NCT04268498 · CT.gov ↗
What to watch
Phase 2Sickle Cell Disease, Thalassemia, Beta, ThalassemiaRecruiting
Est. primary completion 2027-02-09 · NCT05736419 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-02-26 · NCT04133636 · CT.gov ↗
What to watch
March 2027 (3)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-03 · NCT04166565 · CT.gov ↗
What to watch
Early phase / not applicableMultiple MylomaNot yet recruiting
Est. primary completion 2027-03-25 · NCT06876298 · CT.gov ↗
What to watch
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-03-31 · NCT04068597 · CT.gov ↗
What to watch
April 2027 (3)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-04 · NCT02343042 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2027-04 · NCT05558319 · CT.gov ↗
What to watch
Phase 3Plasma Cell MyelomaActive not recruiting
Est. primary completion 2027-04-05 · NCT03319667 · CT.gov ↗
What to watch
May 2027 (1)
Phase 1AL AmyloidosisActive not recruiting
Est. primary completion 2027-05-06 · NCT04754945 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Plasmablastic LymphomaRecruiting
Est. primary completion 2027-07-01 · NCT04915248 · CT.gov ↗
What to watch
August 2027 (3)
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2027-08 · NCT00572169 · CT.gov ↗
What to watch
Phase 2/3Multiple MyelomaRecruiting
Est. primary completion 2027-08 · NCT05665140 · CT.gov ↗
What to watch
Phase 2Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia, Recurrent Burkitt Lymphoma …Recruiting
Est. primary completion 2027-08-01 · NCT03136146 · CT.gov ↗
What to watch
October 2027 (5)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-10 · NCT00869232 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-10 · NCT03004287 · CT.gov ↗
What to watch
Phase 1/2Graft Vs Host DiseaseRecruiting
Est. primary completion 2027-10 · NCT06681922 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2027-10-09 · NCT07789522 · CT.gov ↗
What to watch
Phase 2Recurrent Plasma Cell Myeloma, Refractory Plasma Cell MyelomaActive not recruiting
Est. primary completion 2027-10-30 · NCT03763162 · CT.gov ↗
What to watch
November 2027 (2)
December 2027 (10)
Phase 2MyelomaActive not recruiting
Est. primary completion 2027-12 · NCT00871013 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2027-12 · NCT06158841 · CT.gov ↗
What to watch
Phase 2T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma, Mixed Phenotype Acute LeukemiaRecruiting
Est. primary completion 2027-12 · NCT06390319 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2027-12 · NCT07297329 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-12-20 · NCT04775550 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid Leukemia, TP53Recruiting
Est. primary completion 2027-12-30 · NCT07008638 · CT.gov ↗
What to watch
Phase 2Acute Lymphoblastic Leukemia (ALL)Recruiting
Est. primary completion 2027-12-31 · NCT03590171 · CT.gov ↗
What to watch
Phase 3Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell MyelomaRecruiting
Est. primary completion 2027-12-31 · NCT04566328 · CT.gov ↗
What to watch
Phase 2Relapsed/Refractory Immune ThrombocytopeniaRecruiting
Est. primary completion 2027-12-31 · NCT05599880 · CT.gov ↗
What to watch
2028 (13)
January 2028 (2)
March 2028 (4)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-03 · NCT05272826 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2028-03-25 · NCT05137054 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-03-31 · NCT07045909 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2028-03-31 · NCT07341867 · CT.gov ↗
What to watch
April 2028 (1)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2028-04-26 · NCT06353022 · CT.gov ↗
What to watch
June 2028 (1)
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2028-06 · NCT03617731 · CT.gov ↗
What to watch
July 2028 (2)
August 2028 (1)
Phase 2Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed RemissionRecruiting
Est. primary completion 2028-08 · NCT06034561 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-09-15 · NCT05695508 · CT.gov ↗
What to watch
December 2028 (1)
Phase 1/2Lymphoblastic LeukemiaRecruiting
Est. primary completion 2028-12 · NCT05848687 · CT.gov ↗
What to watch
2029 (11)
January 2029 (3)
Phase 3Hematological Malignancies, Platelet Transfusion Refractoriness (PTR), HLA AntibodiesNot yet recruiting
Est. primary completion 2029-01-01 · NCT07635511 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2029-01-11 · NCT07085728 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2029-01-11 · NCT07764978 · CT.gov ↗
What to watch
February 2029 (2)
May 2029 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2029-05-21 · NCT07222761 · CT.gov ↗
What to watch
June 2029 (1)
Phase 2Plasma Cell Leukemia (PCL)Recruiting
Est. primary completion 2029-06-30 · NCT07652905 · CT.gov ↗
What to watch
July 2029 (1)
Phase 1/2Multiple MyelomaNot yet recruiting
Est. primary completion 2029-07-01 · NCT07601100 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2Waldenstrom MacroglobulinemiaNot yet recruiting
Est. primary completion 2029-08-01 · NCT07464210 · CT.gov ↗
What to watch
2030 (5)
July 2030 (2)
August 2030 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2030-08-30 · NCT07227311 · CT.gov ↗
What to watch
September 2030 (1)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2030-09-02 · NCT06577025 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2030-12-01 · NCT07247097 · CT.gov ↗
What to watch
2031 (3)
May 2031 (1)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2031-05 · NCT03314181 · CT.gov ↗
What to watch
August 2031 (1)
Phase 1Multiple MyelomaNot yet recruiting
Est. primary completion 2031-08-22 · NCT07609706 · CT.gov ↗
What to watch
November 2031 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2031-11 · NCT07285239 · CT.gov ↗
What to watch
2033 (3)
January 2033 (1)
Phase 2AmyloidosisRecruiting
Est. primary completion 2033-01-12 · NCT07224672 · CT.gov ↗
What to watch
June 2033 (1)
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2033-06 · NCT05257083 · CT.gov ↗
What to watch
October 2033 (1)
Phase 3Multiple MyelomaNot yet recruiting
Est. primary completion 2033-10-01 · NCT07624513 · CT.gov ↗
What to watch
2035 (1)
September 2035 (1)
Phase 2/3Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma, Stage IV T Lymphoblastic Leukemia/Lymphoma …Not yet recruiting
Est. primary completion 2035-09-01 · NCT07072585 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.